{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:42:02Z","timestamp":1793403722319,"version":"4.5.0"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sinai University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple sclerosis (MS) has conventionally been considered a prototypical autoimmune disorder. While modern immunotherapies effectively control relapsing conditions, they fail to avert progressive neuroinflammation, neurodegeneration, and remyelination failure. This review offers an evidence-based recontextualization. The pathogenesis of multiple sclerosis is multifactorial, resulting from the interaction of genetic predisposition (especially HLA alleles), environmental factors (particularly Epstein-Barr virus infection), B-cell-mediated autoimmunity, and localized CNS inflammation. In this intricate environment, cellular metabolic dysregulation is a notable factor and potentially adjustable enhancer of disease progression, functioning within the extensive multifactorial pathogenic context, where the bioenergetic programming of immune and neural cells determines inflammatory or protective responses. Proinflammatory Th17 cells and M1 microglia depend on aerobic glycolysis and glutaminolysis regulated by mTOR and HIF-1\u03b1, whereas regulatory T cells, M2 microglia, and neurons require fatty acid oxidation and oxidative phosphorylation via AMPK. In multiple sclerosis, glycolysis disrupts metabolic equilibrium, sustaining chronic neuroinflammation and obstructing repair processes. Established multiple sclerosis therapies, dimethyl fumarate and teriflunomide, exhibit direct, previously unrecognized metabolic effects, validating this pathway as therapeutically viable. Emerging strategies intentionally target these vulnerabilities: glutaminase inhibitors to counteract pathogenic Th17 cells, AMPK activators such as metformin to enhance remyelination, mTOR inhibitors to restore immune tolerance, and NAD\u2009+\u2009precursors to rejuvenate mitochondrial function. Transitioning from broad immunosuppression to specific metabolic reprogramming offers remarkable opportunities for tackling chronic neuroinflammation and correcting remyelination deficits in progressive multiple sclerosis. Immuno-metabolic pharmacology is a promising field; however, its clinical application necessitates stringent validation via meticulously designed trials and dependable biomarkers.<\/jats:p>","DOI":"10.1007\/s10787-026-02350-y","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:58:28Z","timestamp":1785218308000},"page":"5843-5872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination"],"prefix":"10.1007","volume":"34","author":[{"given":"Ghada A.","family":"Badawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab M.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3025-2343","authenticated-orcid":false,"given":"Mohamed N.","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2350_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.720173","author":"EE Abd El-Fattah","year":"2022","unstructured":"Abd El-Fattah EE, Saber S, Youssef ME, Eissa H, El-Ahwany E, Amin NA, Alqarni M, Batiha GE-S, Obaidullah AJ, Kaddah MMY, Ahmed Gaafar AG, Mourad AAE, Mostafa-Hedeab G, Abdelhamid AM (2022) AKT-AMPK\u03b1-mTOR-dependent HIF-1\u03b1 activation is a new therapeutic target for cancer treatment: a novel approach to repositioning the antidiabetic drug Sitagliptin for the management of hepatocellular carcinoma. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.720173","journal-title":"Front Pharmacol"},{"key":"2350_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18092","author":"MA Abdalla","year":"2021","unstructured":"Abdalla MA, Zakhary CM, Rushdi H, Hamdan JA, Youssef KN, Khan A, Khan S (2021) The effectiveness of statins as potential therapy for multiple sclerosis: a systematic review of randomized controlled trials. Cureus. https:\/\/doi.org\/10.7759\/cureus.18092","journal-title":"Cureus"},{"key":"2350_CR3","doi-asserted-by":"publisher","unstructured":"D. Abu-Halaka, E. Rauchbach, H. Zeigerman, O. Tirosh. 2025 DMF, an activator of Nrf2, could mitigate cholic-acid-induced liver damage in high-fat diet. Exploration of Digestive Diseases 4. https:\/\/doi.org\/10.37349\/edd.2025.100581.","DOI":"10.37349\/edd.2025.100581"},{"key":"2350_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2025.111333","volume":"224","author":"AA Abulaban","year":"2025","unstructured":"Abulaban AA, Al-kuraishy HM, Al-Gareeb AI, Ahmed EA, Fawzy MN, Alruwaili M, Alexiou A, Papadakis M, Batiha GE-S (2025) Role of liver X receptor in multiple sclerosis: a long furtive life behind a barrier. Brain Res Bull 224:111333. https:\/\/doi.org\/10.1016\/j.brainresbull.2025.111333","journal-title":"Brain Res Bull"},{"key":"2350_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241233041","author":"L Airas","year":"2024","unstructured":"Airas L, Bermel RA, Chitnis T, Hartung H-P, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H (2024) A review of Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864241233041","journal-title":"Ther Adv Neurol Disord"},{"key":"2350_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110643","author":"AS Al-Dhahi","year":"2025","unstructured":"Al-Dhahi AS, Al-kuraishy HM, Hussain NR, Fawzy MN, Alruwaili M, Waheed HJ, Al-Gareeb AI, Albuhadily AK, Batiha GE-S (2025) The dual role of the COX-2\/PGE2 axis in multiple sclerosis: from pathogenesis to pharmacological inhibition. Clin Immunol. https:\/\/doi.org\/10.1016\/j.clim.2025.110643","journal-title":"Clin Immunol"},{"key":"2350_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s44446-025-00056-w","volume":"34","author":"S Alobid","year":"2026","unstructured":"Alobid S (2026) Targeting the PI3K\/AKT\/mTOR signaling pathway in prostate cancer: molecular dysregulation, therapeutic advances, and future directions. Saudi Pharm J 34:2. https:\/\/doi.org\/10.1007\/s44446-025-00056-w","journal-title":"Saudi Pharm J"},{"key":"2350_CR8","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1093\/brain\/awae013","volume":"147","author":"F Bagnato","year":"2024","unstructured":"Bagnato F, Sati P, Hemond CC, Elliott C, Gauthier SA, Harrison DM, Mainero C, Oh J, Pitt D, Shinohara RT, Smith SA, Trapp B, Azevedo CJ, Calabresi PA, Henry RG, Laule C, Ontaneda D, Rooney WD, Sicotte NL, Reich DS, Absinta M (2024) Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain 147:2913\u20132933. https:\/\/doi.org\/10.1093\/brain\/awae013","journal-title":"Brain"},{"key":"2350_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1474-4422(25)00174-7","volume":"24","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or A, Dufek M, Budincevic H, Drulovic J, Habek M, Hua LH, Weber MS, Thomas P, Napieralski J, Mitzner MC, Ratchford JN, Clayton D, Harp CT, Kuruvilla D, Qi Q, Chen Y-F, Xu Y, Goodyear A, Oh J, Grgic S, Budincevic H, Habek M, Piskac SK, Vuletic V, Ampapa R, Dufek M, Preiningerova JL, Pavelek Z, Drulovic J, Kostic S, Drakulic SM, Smiljanic-Miljkovic D, Vojinovic S, Han\u010dinov\u00e1 V, Florin J, Hua L, Sharlin K (2025) Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol 24:656\u2013666. https:\/\/doi.org\/10.1016\/S1474-4422(25)00174-7","journal-title":"Lancet Neurol"},{"key":"2350_CR10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63852","author":"M Basheeruddin","year":"2024","unstructured":"Basheeruddin M, Qausain S (2024) Hypoxia-inducible factor 1-alpha (HIF-1\u03b1): an essential regulator in cellular metabolic control. Cureus. https:\/\/doi.org\/10.7759\/cureus.63852","journal-title":"Cureus"},{"key":"2350_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1161849","author":"G Bellucci","year":"2023","unstructured":"Bellucci G, Albanese A, Rizzi C, Rinaldi V, Salvetti M, Ristori G (2023) The value of Interferon \u03b2 in multiple sclerosis and novel opportunities for its anti-viral activity: a narrative literature review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1161849","journal-title":"Front Immunol"},{"key":"2350_CR12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/nm.3704","volume":"20","author":"L Berod","year":"2014","unstructured":"Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, Sandouk A, Hesse C, Castro CN, B\u00e4hre H, Tschirner SK, Gorinski N, Gohmert M, Mayer CT, Huehn J, Ponimaskin E, Abraham W-R, M\u00fcller R, Lochner M, Sparwasser T (2014) De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med 20:1327\u20131333. https:\/\/doi.org\/10.1038\/nm.3704","journal-title":"Nat Med"},{"key":"2350_CR13","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4103\/1673-5374.293143","volume":"16","author":"P Bhargava","year":"2021","unstructured":"Bhargava P (2021) Targeting metabolism to treat multiple sclerosis. Neural Regen Res 16:502. https:\/\/doi.org\/10.4103\/1673-5374.293143","journal-title":"Neural Regen Res"},{"key":"2350_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16228","author":"F Binish","year":"2025","unstructured":"Binish F, Xiao J (2025) Deciphering the role of sphingosine 1-phosphate in central nervous system myelination and repair. J Neurochem. https:\/\/doi.org\/10.1111\/jnc.16228","journal-title":"J Neurochem"},{"key":"2350_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-026-01647-w","author":"A Blenkle","year":"2026","unstructured":"Blenkle A, Geladaris A, Weber MS (2026) Microglia-associated progression of multiple sclerosis: target identification and therapeutic engagement in human in vitro models. Exp Mol Med. https:\/\/doi.org\/10.1038\/s12276-026-01647-w","journal-title":"Exp Mol Med"},{"key":"2350_CR16","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1002\/cmdc.202100332","volume":"16","author":"C Borsari","year":"2021","unstructured":"Borsari C, De Pascale M, Wymann MP (2021) Chemical and structural strategies to selectively target mTOR kinase. ChemMedChem 16:2744\u20132759. https:\/\/doi.org\/10.1002\/cmdc.202100332","journal-title":"ChemMedChem"},{"key":"2350_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","volume":"10","author":"I Boutitah-Benyaich","year":"2025","unstructured":"Boutitah-Benyaich I, Eixarch H, Villacieros-\u00c1lvarez J, Hervera A, Cobo-Calvo \u00c1, Montalban X, Espejo C (2025) Multiple sclerosis: molecular pathogenesis and therapeutic intervention. Signal Transduct Target Ther 10:324. https:\/\/doi.org\/10.1038\/s41392-025-02415-4","journal-title":"Signal Transduct Target Ther"},{"key":"2350_CR18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jnnp-2022-329074","volume":"93","author":"JN Brenton","year":"2022","unstructured":"Brenton JN, Lehner-Gulotta D, Woolbright E, Banwell B, Bergqvist AGC, Chen S, Coleman R, Conaway M, Goldman MD (2022) Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits. J Neurol Neurosurg Psychiatry 93:637\u2013644. https:\/\/doi.org\/10.1136\/jnnp-2022-329074","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2350_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1543649","author":"L Brieva","year":"2025","unstructured":"Brieva L, Calles C, Landete L, Oreja-Guevara C (2025) Current challenges in secondary progressive multiple sclerosis: diagnosis, activity detection and treatment. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1543649","journal-title":"Front Immunol"},{"key":"2350_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1556\/1886.2023.00020","volume":"13","author":"JD Brockhoff","year":"2023","unstructured":"Brockhoff JD, Bereswill S, Heimesaat MM (2023) The impact of ketogenic diet on the onset and progression of multiple sclerosis. Eur J Microbiol Immunol (Bp) 13:29\u201336. https:\/\/doi.org\/10.1556\/1886.2023.00020","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"2350_CR21","doi-asserted-by":"publisher","unstructured":"I. Cammarata, G. Sartori, T. Giacomelli, V. Pinna, A. Pinzon Grimaldos, G. De Rosa, G. Matarese, C. Procaccini, D. Mishra, D. Di Mitri, C. Gasperini, G. Guerrera, M. Sambucci, L. Battistini, S. Piconese, Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis, Neurol. Neuroimmunol Neuroinflamm 13 (2026). https:\/\/doi.org\/10.1212\/NXI.0000000000200521.","DOI":"10.1212\/NXI.0000000000200521"},{"key":"2350_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.29245\/2768-5365\/2025\/1.1161","volume":"6","author":"V Carvalho Troiti\u00f1o","year":"2025","unstructured":"Carvalho Troiti\u00f1o V, Pressuto Pennachioni N, Gabriele H\u00f6sch N, Picolo G, Olzon Zambelli V (2025) Benefits of maintaining mitochondrial health in multiple sclerosis. J Anesthesiol Pain Ther 6:6\u201310. https:\/\/doi.org\/10.29245\/2768-5365\/2025\/1.1161","journal-title":"J Anesthesiol Pain Ther"},{"key":"2350_CR23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cmet.2014.04.001","volume":"19","author":"R Cerutti","year":"2014","unstructured":"Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, Leoni V, Schon EA, Dantzer F, Auwerx J, Viscomi C, Zeviani M (2014) NAD+-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 19:1042\u20131049. https:\/\/doi.org\/10.1016\/j.cmet.2014.04.001","journal-title":"Cell Metab"},{"key":"2350_CR24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2217\/imt.14.84","volume":"6","author":"NM Chapman","year":"2014","unstructured":"Chapman NM, Chi H (2014) mTOR signaling, Tregs and immune modulation. Immunotherapy 6:1295\u20131311. https:\/\/doi.org\/10.2217\/imt.14.84","journal-title":"Immunotherapy"},{"key":"2350_CR25","doi-asserted-by":"publisher","unstructured":"J. Chataway, T. Williams, J. Blackstone, N. John, M. Braisher, F. De Angelis, A. Bianchi, A. Calvi, A. Doshi, S. Apap Mangion, C. Wade, E. Bordea, R. Merry, G. Barton, D. Lyle, E. Jarman, D. Mahad, A. Shehu, T. Arun, G. McDonnell, R. Geraldes, M. Craner, C. Hillier, J. Ganesalingam, L. Fisniku, J. Hobart, C. Spilker, N.P. Robertson, S. Kalra, S. Pluchino, S. Harikrishnan, M. Mattoscio, T. Harrower, C. Young, M. Lee, S.K. Chhetri, F. Ahmed, D. Rog, E. Silber, P. Gallagher, M. Duddy, A. Straukiene, R. Nicholas, C. Rice, S. Tebbs, A. Hawton, R. Hunter, G. Giovannoni, O. Ciccarelli, J. Beveridge, S. Nixon, A.J. Thompson, J. Greenwood, O.R. Pearson, N. Evangelou, B. Sharrack, I. Galea, E. Gray, S. Pavitt, S. Chandran, H.L. Ford, C. Frost, J.M. Nicholas, S. Wright, M. Shatila, W. Brownlee, C.A.M.G. Wheeler-Kingshott, F. Barkhof, J. Stutters, F.P. Carrasco, A. Ricciardi, M. Yiannakas, D. MacManus, M. Agiu, V. Bassan, T. Beyene, S. Conway, B. Fneich, A.H. Jimenez, S. Pullinger, E. Samdanidou, M. Wynne, L. Crisp, J. Parker, J. Flight, L. Deane, P. Connick, C. Jacob, S. Kaninia, D. Paling, H. Ford, L. Fernandes, M. Vinjam, G. Ingram, C. Rickards, M. Hill, C. Allen, M. Belhag, F. Magill, S. Ramsay, D. Cullen, H. Birmingham, A. Cavey, J. Dube, M. Davis, J. Aram, J. Newman, O. Almasri, D. Lashley, O. Quinn, R. Bellfield, S. Ellis, E. Tallantyre, C. Butcher, N. Guck, L. Peruzzotti-Jametti, A. Chaudhuri, E. Visentin, G. Fawehinmi, L. Azzopardi, C. O\u2019Reilly, S. Acres, S. Statton, R. Mills, H. Arndt, M. Maskery, M. Khalil, V. Parker, N. Vinod, G. Dervanoulis, N. Rhule, L. Robson, C. Marshall, K. Bamforth, A. Kalil, L. Cabreros, T. Minton, Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial, The Lancet 406 (2025) 1611\u20131624. https:\/\/doi.org\/10.1016\/S0140-6736(25)01039-6.","DOI":"10.1016\/S0140-6736(25)01039-6"},{"key":"2350_CR26","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4103\/NRR.NRR-D-24-01495","volume":"21","author":"B Chen","year":"2026","unstructured":"Chen B (2026) Metformin remodels the myelin landscape. Neural Regen Res 21:1120\u20131121. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-01495","journal-title":"Neural Regen Res"},{"key":"2350_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1376252","author":"D-Q Chen","year":"2024","unstructured":"Chen D-Q, Han J, Liu H, Feng K, Li P (2024) Targeting pyruvate kinase M2 for the treatment of kidney disease front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2024.1376252","journal-title":"Pharmacol"},{"key":"2350_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70657","author":"J Chen","year":"2025","unstructured":"Chen J, Liu B, Yao X, Yang X, Sun J, Yi J, Xue F, Zhang J, Shen Y, Chen B, Sun H (2025) AMPK\/SIRT1\/PGC-1\u03b1 signaling pathway: molecular mechanisms and targeted strategies from energy homeostasis regulation to disease therapy. CNS Neurosci Ther. https:\/\/doi.org\/10.1111\/cns.70657","journal-title":"CNS Neurosci Ther"},{"key":"2350_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02187-y","volume":"18","author":"J Cheng","year":"2021","unstructured":"Cheng J, Zhang R, Xu Z, Ke Y, Sun R, Yang H, Zhang X, Zhen X, Zheng L-T (2021) Early glycolytic reprogramming controls microglial inflammatory activation. J Neuroinflammation 18:129. https:\/\/doi.org\/10.1186\/s12974-021-02187-y","journal-title":"J Neuroinflammation"},{"key":"2350_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.192286","author":"S-C Choi","year":"2025","unstructured":"Choi S-C, Ge Y, Joshi MV, Jimenez D, Castellanos Garcia A, LaPlante C, Padilla LT, Ma C, Zhang N, Rathmell JC, Mohamadzadeh M, Morel L (2025) Intrinsic T cell glutaminolysis promotes autoimmunity in lupus-prone mice. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.192286","journal-title":"JCI Insight"},{"key":"2350_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acn3.52017","volume":"11","author":"PK Coyle","year":"2024","unstructured":"Coyle PK, Freedman MS, Cohen BA, Cree BAC, Markowitz CE (2024) Sphingosine 1\u2010phosphate receptor modulators in multiple sclerosis treatment: a practical review. Ann Clin Transl Neurol 11:842\u2013855. https:\/\/doi.org\/10.1002\/acn3.52017","journal-title":"Ann Clin Transl Neurol"},{"key":"2350_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241306684","author":"A Dal-Bianco","year":"2024","unstructured":"Dal-Bianco A, Oh J, Sati P, Absinta M (2024) Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864241306684","journal-title":"Ther Adv Neurol Disord"},{"key":"2350_CR33","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1080\/17568919.2025.2571029","volume":"17","author":"R Das","year":"2025","unstructured":"Das R, Sharma S, Ambast PK, Shard A (2025) Recent progress in the development of small molecule pyruvate kinase M2 inhibitors: 2020\u20132025. Future Med Chem 17:2771\u20132804. https:\/\/doi.org\/10.1080\/17568919.2025.2571029","journal-title":"Future Med Chem"},{"key":"2350_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1748360","author":"MR de Oliveira","year":"2026","unstructured":"de Oliveira MR (2026) Dimethyl fumarate and mitochondrial physiology: implications for neurological disorders. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2026.1748360","journal-title":"Front Pharmacol"},{"key":"2350_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bbacli.2016.10.004","volume":"6","author":"L De Riccardis","year":"2016","unstructured":"De Riccardis L, Ferramosca A, Danieli A, Trianni G, Zara V, De Robertis F, Maffia M (2016) Metabolic response to glatiramer acetate therapy in multiple sclerosis patients. BBA Clin 6:131\u2013137. https:\/\/doi.org\/10.1016\/j.bbacli.2016.10.004","journal-title":"BBA Clin"},{"key":"2350_CR36","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.immuni.2022.09.005","volume":"55","author":"K De Vlaminck","year":"2022","unstructured":"De Vlaminck K, Van Hove H, Kancheva D, Scheyltjens I, Pombo Antunes AR, Bastos J, Vara-Perez M, Ali L, Mampay M, Deneyer L, Miranda JF, Cai R, Bouwens L, De Bundel D, Caljon G, Stijlemans B, Massie A, Van Ginderachter JA, Vandenbroucke RE, Movahedi K (2022) Differential plasticity and fate of brain-resident and recruited macrophages during the onset and resolution of neuroinflammation. Immunity 55:2085-2102.e9. https:\/\/doi.org\/10.1016\/j.immuni.2022.09.005","journal-title":"Immunity"},{"key":"2350_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113310","volume":"329","author":"NA Devanney","year":"2020","unstructured":"Devanney NA, Stewart AN, Gensel JC (2020) Microglia and macrophage metabolism in CNS injury and disease: the role of immunometabolism in neurodegeneration and neurotrauma. Exp Neurol 329:113310. https:\/\/doi.org\/10.1016\/j.expneurol.2020.113310","journal-title":"Exp Neurol"},{"key":"2350_CR38","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.4103\/NRR.NRR-D-24-00961","volume":"21","author":"NK Dhaliwal","year":"2026","unstructured":"Dhaliwal NK, Muffat J, Li Y (2026) MTORC1 and mTORC2 synergy in human neural development, disease, and regeneration. Neural Regen Res 21:1552\u20131553. https:\/\/doi.org\/10.4103\/NRR.NRR-D-24-00961","journal-title":"Neural Regen Res"},{"key":"2350_CR39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/v18020160","volume":"18","author":"X Ding","year":"2026","unstructured":"Ding X, Liu L, Wei H (2026) Beyond viral restriction: the metabolic dimensions of interferon-stimulated genes in antiviral immunity. Viruses 18:160. https:\/\/doi.org\/10.3390\/v18020160","journal-title":"Viruses"},{"key":"2350_CR40","doi-asserted-by":"publisher","unstructured":"P.D. Drew, J. Xu, M.K. Racke, PPAR-\u03b3: Therapeutic Potential for Multiple Sclerosis, PPAR Res. 2008 (2008). https:\/\/doi.org\/10.1155\/2008\/627463.","DOI":"10.1155\/2008\/627463"},{"key":"2350_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","volume":"24","author":"L Dumitrescu","year":"2023","unstructured":"Dumitrescu L, Papathanasiou A, Coclitu C, Garjani A, Evangelou N, Constantinescu CS, Popescu BO, Tanasescu R (2023) An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacother 24:495\u2013509. https:\/\/doi.org\/10.1080\/14656566.2023.2178898","journal-title":"Expert Opin Pharmacother"},{"key":"2350_CR42","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/ana.20736","volume":"59","author":"R Dutta","year":"2006","unstructured":"Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478\u2013489. https:\/\/doi.org\/10.1002\/ana.20736","journal-title":"Ann Neurol"},{"key":"2350_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21175957","volume":"21","author":"A Dziedzic","year":"2020","unstructured":"Dziedzic A, Saluk-Bijak J, Miller E, Bijak M (2020) Metformin as a potential agent in the treatment of multiple sclerosis. Int J Mol Sci 21:5957. https:\/\/doi.org\/10.3390\/ijms21175957","journal-title":"Int J Mol Sci"},{"key":"2350_CR44","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0019-2025","volume":"34","author":"D Elia","year":"2025","unstructured":"Elia D, Harari S, Fan L, Diesler R, Henske EP (2025) Novel treatment strategies for lymphangioleiomyomatosis: a narrative review. Eur Respir Rev 34:250019. https:\/\/doi.org\/10.1183\/16000617.0019-2025","journal-title":"Eur Respir Rev"},{"key":"2350_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264128","author":"ML Elkjaer","year":"2023","unstructured":"Elkjaer ML, Waede MR, Kingo C, Damsbo K, Illes Z (2023) Expression of Bruton\u00b4s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1264128","journal-title":"Front Immunol"},{"key":"2350_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.70219","author":"P Engskog-Vlachos","year":"2025","unstructured":"Engskog-Vlachos P, Engskog MKR, Skandik M, Grabert K, Moruzzi N, St-Pierre M, Osman AM, Sylaidi T, Blomgren K, Berggren P, Joseph B (2025) metabolic profiling reveals a glycolytic shift and an IRG1\/Itaconate\/NF2L2 axis regulating neurotoxic oxidative stress in inflammatory microglia. J Neurochem. https:\/\/doi.org\/10.1111\/jnc.70219","journal-title":"J Neurochem"},{"key":"2350_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2026.110704","author":"MN Fawzy","year":"2026","unstructured":"Fawzy MN, Badawi GA, El-Sayed RM (2026a) Immune dysregulation in fibromyalgia: targeting the NLRP3 inflammasome-ferroptosis axis as a novel therapeutic strategy for chronic pain. Clin Immunol. https:\/\/doi.org\/10.1016\/j.clim.2026.110704","journal-title":"Clin Immunol"},{"key":"2350_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2026.111042","volume":"297","author":"MN Fawzy","year":"2026","unstructured":"Fawzy MN, Abdelaziz AM, Shokr MM, Fathy MK (2026b) Targeting the microbiome-NLRP3-ferroptosis axis in multiple sclerosis: neuropharmacological implications for microglial dysfunction and demyelination. Neuropharmacology 297:111042. https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111042","journal-title":"Neuropharmacology"},{"key":"2350_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-026-02490-4","author":"MN Fawzy","year":"2026","unstructured":"Fawzy MN, Fathy MK (2026) Targeting the gut-brain-ferroptosis axis: molecular mechanisms and therapeutic potential in Alzheimer\u2019s disease and epilepsy. J Molecular Neurosci. https:\/\/doi.org\/10.1007\/s12031-026-02490-4","journal-title":"J Molecular Neurosci"},{"key":"2350_CR50","doi-asserted-by":"publisher","unstructured":"M.N. Fawzy, E.A. Abd El-Haleim, H.F. Zaki, H.A. Salem, R.M. El-Sayed, Mitigating seizure-induced cognitive deficits in mice induced with pentylenetetrazol by roflumilast through targeting the NLRP3 inflammasome\/BDNF\/SIRT3 pathway and regulating ferroptosis, Life Sci. 366\u2013367 (2025) 123488. https:\/\/doi.org\/10.1016\/j.lfs.2025.123488.","DOI":"10.1016\/j.lfs.2025.123488"},{"key":"2350_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986847","author":"X Feng","year":"2022","unstructured":"Feng X, Li X, Liu N, Hou N, Sun X, Liu Y (2022) Glutaminolysis and CD4+ T-cell metabolism in autoimmunity: from pathogenesis to therapy prospects. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.986847","journal-title":"Front Immunol"},{"key":"2350_CR52","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/S11427-024-2653-2","volume":"68","author":"J Feng","year":"2025","unstructured":"Feng J, Tang S, Yang X, Zhang M, Li Z, Zhang S, Han Y, Li Y, Monnier PP, Yu G, Zheng P, Zhang C, Xu K, Qin X (2025) Landscapes of gut microbiome and blood metabolomic signatures in relapsing remitting multiple sclerosis. Sci China Life Sci 68:1042\u20131056. https:\/\/doi.org\/10.1007\/S11427-024-2653-2","journal-title":"Sci China Life Sci"},{"key":"2350_CR53","doi-asserted-by":"publisher","first-page":"165","DOI":"10.7224\/1537-2073.2018-063","volume":"22","author":"M Filipi","year":"2020","unstructured":"Filipi M, Jack S (2020) Interferons in the treatment of multiple sclerosis. Int J MS Care 22:165\u2013172. https:\/\/doi.org\/10.7224\/1537-2073.2018-063","journal-title":"Int J MS Care"},{"key":"2350_CR54","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2174\/011570159X360729250319064959","volume":"23","author":"C Finocchiaro","year":"2025","unstructured":"Finocchiaro C, Chisari CG, Lo Fermo S, D\u2019Amico E, Parrinello NL, Romano A, Palumbo GA, Marino S, Corsale AM, Di Raimondo F, Zappia M, Patti F (2025) In vivo effects of disease-modifying therapies on immunological subsets in patients with relapsing-remitting multiple sclerosis. Curr Neuropharmacol 23:1783\u20131796. https:\/\/doi.org\/10.2174\/011570159X360729250319064959","journal-title":"Curr Neuropharmacol"},{"key":"2350_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-01124-x","volume":"5","author":"D Freuer","year":"2025","unstructured":"Freuer D, Linseisen J, Schmitz T, Thorand B, Peters A, Petrera A, Heier M, Meisinger C (2025) Pleiotropic effects between statin intake and inflammation parameters in two distinct population-based studies. Commun Med 5:387. https:\/\/doi.org\/10.1038\/s43856-025-01124-x","journal-title":"Commun Med"},{"key":"2350_CR56","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.molcel.2017.05.032","volume":"66","author":"D Garcia","year":"2017","unstructured":"Garcia D, Shaw RJ (2017) AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell 66:789\u2013800. https:\/\/doi.org\/10.1016\/j.molcel.2017.05.032","journal-title":"Mol Cell"},{"key":"2350_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.732120","author":"D Garc\u00eda-Rodr\u00edguez","year":"2021","unstructured":"Garc\u00eda-Rodr\u00edguez D, Gim\u00e9nez-Cassina A (2021) Ketone bodies in the brain beyond fuel metabolism: from excitability to gene expression and cell signaling. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2021.732120","journal-title":"Front Mol Neurosci"},{"key":"2350_CR58","doi-asserted-by":"publisher","DOI":"10.18632\/aging.206198","author":"R Garc\u00eda-Salas","year":"2025","unstructured":"Garc\u00eda-Salas R, Cilleros-Holgado P, Di Spirito A, G\u00f3mez-Fern\u00e1ndez D, Pi\u00f1ero-P\u00e9rez R, Romero-Dom\u00ednguez JM, \u00c1lvarez-C\u00f3rdoba M, Reche-L\u00f3pez D, Romero-Gonz\u00e1lez A, L\u00f3pez-Cabrera A, S\u00e1nchez-Alc\u00e1zar JA (2025) Mitochondrial dysfunction, iron accumulation, lipid peroxidation, and inflammasome activation in cellular models derived from patients with multiple sclerosis. Aging (Albany NY). https:\/\/doi.org\/10.18632\/aging.206198","journal-title":"Aging (Albany NY)"},{"key":"2350_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102984","volume":"20","author":"C Geier","year":"2021","unstructured":"Geier C, Perl A (2021) Therapeutic mTOR blockade in systemic autoimmunity: implications for antiviral immunity and extension of lifespan. Autoimmun Rev 20:102984. https:\/\/doi.org\/10.1016\/j.autrev.2021.102984","journal-title":"Autoimmun Rev"},{"key":"2350_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02730-0","volume":"147","author":"A Geladaris","year":"2024","unstructured":"Geladaris A, Torke S, Saberi D, Alankus YB, Streit F, Zechel S, Stadelmann-Nessler C, Fischer A, Boschert U, H\u00e4usler D, Weber MS (2024) BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair. Acta Neuropathol 147:75. https:\/\/doi.org\/10.1007\/s00401-024-02730-0","journal-title":"Acta Neuropathol"},{"key":"2350_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1729690","author":"F Getachew","year":"2025","unstructured":"Getachew F, Hu J, Benamar M (2025) Metabolic regulation of regulatory T cells: mechanisms, heterogeneity, and implications in disease. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1729690","journal-title":"Front Immunol"},{"key":"2350_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00401-026-02984-w","volume":"151","author":"A Giordano","year":"2026","unstructured":"Giordano A, Stridh P, Preziosa P, Pisa M, Lerma-Martin C, Sorosina M, Mascia E, Santoro S, Misra K, Clarelli F, Ferr\u00e8 L, Needhamsen M, Manouchehrinia A, Missaglia M, Moridi T, Shchetynsky K, Ouellette R, Harroud A, de Vries E, Kuttikkatte SB, Piehl F, Alfredsson L, Hillert J, Olsson T, Fugger L, Attfield K, Granberg T, Schirmer L, Absinta M, Jagodic M, DeLuca GC, Rocca MA, Filippi M, Kockum I, Esposito F (2026) A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis. Acta Neuropathol 151:12. https:\/\/doi.org\/10.1007\/s00401-026-02984-w","journal-title":"Acta Neuropathol"},{"key":"2350_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-63","volume":"9","author":"E Gray","year":"2012","unstructured":"Gray E, Ginty M, Kemp K, Scolding N, Wilkins A (2012) The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J Neuroinflammation 9:561. https:\/\/doi.org\/10.1186\/1742-2094-9-63","journal-title":"J Neuroinflammation"},{"key":"2350_CR64","doi-asserted-by":"publisher","first-page":"10116","DOI":"10.1038\/s41467-024-54430-8","volume":"15","author":"RC Gruber","year":"2024","unstructured":"Gruber RC, Wirak GS, Blazier AS, Lee L, Dufault MR, Hagan N, Chretien N, LaMorte M, Hammond TR, Cheong A, Ryan SK, Macklin A, Zhang M, Pande N, Havari E, Turner TJ, Chomyk A, Christie E, Trapp BD, Ofengeim D (2024) BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis. Nat Commun 15:10116. https:\/\/doi.org\/10.1038\/s41467-024-54430-8","journal-title":"Nat Commun"},{"key":"2350_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111810","volume":"131","author":"H Gu","year":"2024","unstructured":"Gu H, Wang Z, Xie X, Chen H, Ouyang J, Wu R, Chen Z (2024) HIF-1\u03b1 induced by hypoxic condition regulates Treg\/Th17 axis polarization in chronic immune thrombocytopenia. Int Immunopharmacol 131:111810. https:\/\/doi.org\/10.1016\/j.intimp.2024.111810","journal-title":"Int Immunopharmacol"},{"key":"2350_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2024.102511","volume":"92","author":"J H\u00e4rm","year":"2025","unstructured":"H\u00e4rm J, Fan Y-T, Brenner D (2025) Navigating the metabolic landscape of regulatory T cells: from autoimmune diseases to tumor microenvironments. Curr Opin Immunol 92:102511. https:\/\/doi.org\/10.1016\/j.coi.2024.102511","journal-title":"Curr Opin Immunol"},{"key":"2350_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62966-4","volume":"14","author":"C He","year":"2024","unstructured":"He C, Li Z, Yu W, Luo R, Zhou J, He J, Chen Q, Song Z, Cheng S (2024) LncRNA TUG1 mediates microglial inflammatory activation by regulating glucose metabolic reprogramming. Sci Rep 14:12143. https:\/\/doi.org\/10.1038\/s41598-024-62966-4","journal-title":"Sci Rep"},{"key":"2350_CR68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221544120","author":"M Heming","year":"2023","unstructured":"Heming M, Wiendl H (2023) Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy. Proceedings National Academy Sci. https:\/\/doi.org\/10.1073\/pnas.2221544120","journal-title":"Proceedings National Academy Sci"},{"key":"2350_CR69","doi-asserted-by":"publisher","unstructured":"K.R. Hollinger, M.D. Smith, L.A. Kirby, E. Prchalova, J. Alt, R. Rais, P.A. Calabresi, B.S. Slusher, Glutamine antagonism attenuates physical and cognitive deficits in a model of MS, Neurol. Neuroimmunol. Neuroinflamm. 6 (2019). https:\/\/doi.org\/10.1212\/NXI.0000000000000609.","DOI":"10.1212\/NXI.0000000000000609"},{"key":"2350_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15030248","volume":"15","author":"BYA Hollingworth","year":"2025","unstructured":"Hollingworth BYA, Pallier PN, Jenkins SI, Chen R (2025) Hypoxic neuroinflammation in the pathogenesis of multiple sclerosis. Brain Sci (Basel) 15:248. https:\/\/doi.org\/10.3390\/brainsci15030248","journal-title":"Brain Sci (Basel)"},{"key":"2350_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm8182","volume-title":"OXPHOS Promotes Apoptotic Resistance and Cellular Persistence in TH17 cells in the Periphery and Tumor Microenvironment","author":"HS Hong","year":"2022","unstructured":"Hong HS, Mbah NE, Shan M, Loesel K, Lin L, Sajjakulnukit P, Correa LO, Andren A, Lin J, Hayashi A, Magnuson B, Chen J, Li Z, Xie Y, Zhang L, Goldstein DR, Carty SA, Lei YL, Opipari AW, Arg\u00fcello RJ, Kryczek I, Kamada N, Zou W, Franchi L, Lyssiotis CA (2022) OXPHOS Promotes Apoptotic Resistance and Cellular Persistence in TH17 cells in the Periphery and Tumor Microenvironment. Immunol, Sci. https:\/\/doi.org\/10.1126\/sciimmunol.abm8182"},{"key":"2350_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1687755","author":"Y Hu","year":"2025","unstructured":"Hu Y, Zhao Q, Dai H, Wu Y, Tang X, Zhang N, Jiang H, Rui H, Liu B (2025) Metabolic reprogramming as a therapeutic target for modulating the Th17\/Treg balance in autoimmune diseases: a comprehensive review. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1687755","journal-title":"Front Immunol"},{"key":"2350_CR73","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nature09978","volume":"472","author":"JR Huh","year":"2011","unstructured":"Huh JR, Leung MWL, Huang P, Ryan DA, Krout MR, Malapaka RRV, Chow J, Manel N, Ciofani M, Kim SV, Cuesta A, Santori FR, Lafaille JJ, Xu HE, Gin DY, Rastinejad F, Littman DR (2011) Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR\u03b3t activity. Nature 472:486\u2013490. https:\/\/doi.org\/10.1038\/nature09978","journal-title":"Nature"},{"key":"2350_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.735463","author":"C Iperi","year":"2021","unstructured":"Iperi C, Bordron A, Dueymes M, Pers J-O, Jamin C (2021) Metabolic program of regulatory B lymphocytes and influence in the control of malignant and autoimmune situations. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.735463","journal-title":"Front Immunol"},{"key":"2350_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176912","volume":"982","author":"A Jamshidi-Parsian","year":"2024","unstructured":"Jamshidi-Parsian A, Jenkins SV, Tran A, Bragg A, Davis R, Griffin C, Siegel E, Dings RPM, Griffin RJ, Boysen G (2024) CB-839 induces reversible dormancy in lung tumor-cells. Eur J Pharmacol 982:176912. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176912","journal-title":"Eur J Pharmacol"},{"key":"2350_CR76","doi-asserted-by":"publisher","unstructured":"P. Jiang, Z. Jiang, S. Li, Y.-X. Li, Y. Chen, X. Li, The suppressive role of GLS in radiosensitivity and irradiation-induced immune response in LUAD: integrating bioinformatics and experimental insights, Front. Immunol. 16 (2025). https:\/\/doi.org\/10.3389\/fimmu.2025.1582587.","DOI":"10.3389\/fimmu.2025.1582587"},{"key":"2350_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112253","volume":"134","author":"Z-Q Jing","year":"2024","unstructured":"Jing Z-Q, Luo Z-Q, Chen S-R, Sun Z-J (2024) Heterogeneity of myeloid cells in common cancers: single cell insights and targeting strategies. Int Immunopharmacol 134:112253. https:\/\/doi.org\/10.1016\/j.intimp.2024.112253","journal-title":"Int Immunopharmacol"},{"key":"2350_CR78","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/intimm\/dxae007","volume":"36","author":"M Kates","year":"2024","unstructured":"Kates M, Saibil SD (2024) Reprogramming T-cell metabolism to enhance adoptive cell therapies. Int Immunol 36:261\u2013278. https:\/\/doi.org\/10.1093\/intimm\/dxae007","journal-title":"Int Immunol"},{"key":"2350_CR79","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jnc.15206","volume":"158","author":"DK Kaushik","year":"2021","unstructured":"Kaushik DK, Yong VW (2021) Metabolic needs of brain\u2010infiltrating leukocytes and microglia in multiple sclerosis. J Neurochem 158:14\u201324. https:\/\/doi.org\/10.1111\/jnc.15206","journal-title":"J Neurochem"},{"key":"2350_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1362629","author":"A-V De Keersmaecker","year":"2024","unstructured":"De Keersmaecker A-V, Van Doninck E, Popescu V, Willem L, Cambron M, Laureys G, M. D\u2019 Haeseleer, M. Bjerke, E. Roelant, M. Lemmerling, M.B. D\u2019hooghe, J. Derdelinckx, T. Reynders, B. Willekens. (2024) A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1362629","journal-title":"Front Immunol"},{"key":"2350_CR81","doi-asserted-by":"publisher","unstructured":"F. Kemp, E.L. Braverman, C.A. Byersdorfer, Fatty acid oxidation in immune function, Front. Immunol. 15 (2024). https:\/\/doi.org\/10.3389\/fimmu.2024.1420336.","DOI":"10.3389\/fimmu.2024.1420336"},{"key":"2350_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07838-z","volume":"16","author":"OA Khomich","year":"2025","unstructured":"Khomich OA, Giavalisco P, Parent R, Krasnov GS, Tessarz P, Meuleman P, Burm R, Zakirova NF, Molle J, Batbold E, Gottlieb E, Zoulim F, Ivanov AV, Bartosch B (2025) IFN-\u03b2 production promotes metabolic rewiring and protection against oxidative stress in hepatitis delta virus-infected hepatocyte cultures. Cell Death Dis 16:534. https:\/\/doi.org\/10.1038\/s41419-025-07838-z","journal-title":"Cell Death Dis"},{"key":"2350_CR83","doi-asserted-by":"publisher","unstructured":"K. Khoy, D. Mariotte, G. Defer, G. Petit, O. Toutirais, B. Le Mauff, Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring, Front. Immunol. 11 (2020). https:\/\/doi.org\/10.3389\/fimmu.2020.549842.","DOI":"10.3389\/fimmu.2020.549842"},{"key":"2350_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108432","volume":"246","author":"Y Kihara","year":"2023","unstructured":"Kihara Y, Chun J (2023) Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis. Pharmacol Ther 246:108432. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108432","journal-title":"Pharmacol Ther"},{"key":"2350_CR85","doi-asserted-by":"publisher","unstructured":"J. Kim, J. Li, J. Wei, S.A. Lim, Regulatory T Cell Metabolism: A Promising Therapeutic Target for Cancer Treatment?, Immune Netw. 25 (2025). https:\/\/doi.org\/10.4110\/in.2025.25.e13.","DOI":"10.4110\/in.2025.25.e13"},{"key":"2350_CR86","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","volume":"72","author":"P Kivis\u00e4kk","year":"2009","unstructured":"Kivis\u00e4kk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, Khoury SJ (2009) Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72:1922\u20131930. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a8266f","journal-title":"Neurology"},{"key":"2350_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aas9822","author":"J Klarquist","year":"2018","unstructured":"Klarquist J, Chitrakar A, Pennock ND, Kilgore AM, Blain T, Zheng C, Danhorn T, Walton K, Jiang L, Sun J, Hunter CA, D\u2019Alessandro A, Kedl RM (2018) Clonal expansion of vaccine-elicited T cells is independent of aerobic glycolysis. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aas9822","journal-title":"Sci Immunol"},{"key":"2350_CR88","doi-asserted-by":"publisher","unstructured":"L. Klotz, M. Saraste, L. Airas, T. Kuhlmann, Multiple sclerosis: 2024 update, Free Neuropathol. 6 (2025). https:\/\/doi.org\/10.17879\/freeneuropathology-2025-6762.","DOI":"10.17879\/freeneuropathology-2025-6762"},{"key":"2350_CR89","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1073\/pnas.1714717115","volume":"115","author":"M Kono","year":"2018","unstructured":"Kono M, Yoshida N, Maeda K, Tsokos GC (2018) Transcriptional factor ICER promotes glutaminolysis and the generation of Th17 cells. Proc Natl Acad Sci U S A 115:2478\u20132483. https:\/\/doi.org\/10.1073\/pnas.1714717115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2350_CR90","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/cei.12261","volume":"176","author":"T Koudriavtseva","year":"2014","unstructured":"Koudriavtseva T, Sbardella E, Trento E, Bordignon V, D\u2019Agosto G, Cordiali-Fei P (2014) Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. Clin Exp Immunol 176:320\u2013326. https:\/\/doi.org\/10.1111\/cei.12261","journal-title":"Clin Exp Immunol"},{"key":"2350_CR91","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer J, Bar-Or A, Turner TJ, Wiendl H (2023) Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol 19:289\u2013304. https:\/\/doi.org\/10.1038\/s41582-023-00800-7","journal-title":"Nat Rev Neurol"},{"key":"2350_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2024.100928","volume":"43","author":"S Lai","year":"2025","unstructured":"Lai S, Wu X, Liu Y, Liu B, Wu H, Ma K (2025) Interaction between Th17 and central nervous system in multiple sclerosis. Brain Behav Immun Health 43:100928. https:\/\/doi.org\/10.1016\/j.bbih.2024.100928","journal-title":"Brain Behav Immun Health"},{"key":"2350_CR93","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40265-026-02324-y","volume":"86","author":"J Lambe","year":"2026","unstructured":"Lambe J, Fox RJ (2026) Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis. Drugs 86:989\u20131012. https:\/\/doi.org\/10.1007\/s40265-026-02324-y","journal-title":"Drugs"},{"key":"2350_CR94","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41574-024-00992-y","volume":"20","author":"HT Langer","year":"2024","unstructured":"Langer HT, Rohm M, Goncalves MD, Sylow L (2024) AMPK as a mediator of tissue preservation: time for a shift in dogma? Nat Rev Endocrinol 20:526\u2013540. https:\/\/doi.org\/10.1038\/s41574-024-00992-y","journal-title":"Nat Rev Endocrinol"},{"key":"2350_CR95","doi-asserted-by":"publisher","unstructured":"H.A.K. Lapatto, M. Kuusela, A. Heikkinen, M. Muniandy, B.W. van der Kolk, S. Gopalakrishnan, N. P\u00f6ll\u00e4nen, M. Sandvik, M.S. Schmidt, S. Heinonen, S. Saari, J. Kuula, A. Hakkarainen, J. Tampio, T. Saarinen, M.-R. Taskinen, N. Lundbom, P.-H. Groop, M. Tiirola, P. Katajisto, M. Lehtonen, C. Brenner, J. Kaprio, S. Pekkala, M. Ollikainen, K.H. Pietil\u00e4inen, E. Pirinen, Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study, Sci. Adv. 9 (2023). https:\/\/doi.org\/10.1126\/sciadv.add5163.","DOI":"10.1126\/sciadv.add5163"},{"key":"2350_CR96","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cmet.2024.12.009","volume":"37","author":"WD Lee","year":"2025","unstructured":"Lee WD, Weilandt DR, Liang L, MacArthur MR, Jaiswal N, Ong O, Mann CG, Chu Q, Hunter CJ, Ryseck R-P, Lu W, Oschmann AM, Cowan AJ, TeSlaa TA, Bartman CR, Jang C, Baur JA, Titchenell PM, Rabinowitz JD (2025) Lactate homeostasis is maintained through regulation of glycolysis and lipolysis. Cell Metab 37:758-771.e8. https:\/\/doi.org\/10.1016\/j.cmet.2024.12.009","journal-title":"Cell Metab"},{"key":"2350_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451032","volume-title":"Interferon \u03b1 and \u03b2 induce differential transcriptional and functional metabolic phenotypes in human macrophages and blunt glycolysis in response to antigenic stimuli","author":"G Leisching","year":"2024","unstructured":"Leisching G, Yennemadi A, Gogan K (2024) Interferon \u03b1 and \u03b2 induce differential transcriptional and functional metabolic phenotypes in human macrophages and blunt glycolysis in response to antigenic stimuli. J. Immunol, Eur. https:\/\/doi.org\/10.1002\/eji.202451032"},{"key":"2350_CR98","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41593-024-01796-z","volume":"27","author":"C Lerma-Martin","year":"2024","unstructured":"Lerma-Martin C, Badia-i-Mompel P, Ramirez Flores RO, Sekol P, Sch\u00e4fer PSL, Riedl CJ, Hofmann A, Th\u00e4wel T, W\u00fcnnemann F, Ibarra-Arellano MA, Trobisch T, Eisele P, Schapiro D, Haeussler M, Hametner S, Saez-Rodriguez J, Schirmer L (2024) Cell type mapping reveals tissue niches and interactions in subcortical multiple sclerosis lesions. Nat Neurosci 27:2354\u20132365. https:\/\/doi.org\/10.1038\/s41593-024-01796-z","journal-title":"Nat Neurosci"},{"key":"2350_CR99","doi-asserted-by":"publisher","first-page":"18175","DOI":"10.1021\/acs.jmedchem.1c01711","volume":"64","author":"C Li","year":"2021","unstructured":"Li C, Yang X, Luo Y, Liu H, Zhong X, Zhou X, Zeng T, Tao L, Zhou Y, Gou K, Yang X, Liu X, Chen Q, Zhao Y, Luo Y (2021) Design, synthesis, and biological evaluation of a novel series of teriflunomide derivatives as potent human dihydroorotate dehydrogenase inhibitors for malignancy treatment. J Med Chem 64:18175\u201318192. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01711","journal-title":"J Med Chem"},{"key":"2350_CR100","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00401-022-02411-w","volume":"143","author":"R Li","year":"2022","unstructured":"Li R, Tang H, Burns JC, Hopkins BT, Le Coz C, Zhang B, de Barcelos IP, Romberg N, Goldstein AC, Banwell BL, Luning Prak ET, Mingueneau M, Bar-Or A (2022) BTK inhibition limits B-cell\u2013T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathol 143:505\u2013521. https:\/\/doi.org\/10.1007\/s00401-022-02411-w","journal-title":"Acta Neuropathol"},{"key":"2350_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/acel.70189","author":"B Li","year":"2025","unstructured":"Li B, Wang S, Kerman B, Hugo C, Shwab EK, Shu C, Chiba\u2010Falek O, Arvanitakis Z, Yassine HN (2025b) Microglial states are susceptible to senescence and cholesterol dysregulation in Alzheimer\u2019s disease. Aging Cell. https:\/\/doi.org\/10.1111\/acel.70189","journal-title":"Aging Cell"},{"key":"2350_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.590884","author":"X Li","year":"2020","unstructured":"Li X, Zhang B, Liu W, Sun M, Zhang Y, Liu H, Wang M (2020) Rapamycin alleviates the symptoms of multiple sclerosis in experimental autoimmune encephalomyelitis (EAE) through mediating the TAM-TLRs-SOCS pathway. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.590884","journal-title":"Front Neurol"},{"key":"2350_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1232820","author":"J Li","year":"2023","unstructured":"Li J, Zhao M, Luo W, Huang J, Zhao B, Zhou Z (2023) B cell metabolism in autoimmune diseases: signaling pathways and interventions. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1232820","journal-title":"Front Immunol"},{"key":"2350_CR104","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk0865","volume-title":"Oxidative phosphorylation regulates B cell effector cytokines and promotes inflammation in multiple sclerosis","author":"R Li","year":"2024","unstructured":"Li R, Lei Y, Rezk A, Espinoza DA, Wang J, Feng H, Zhang B, Barcelos IP, Zhang H, Yu J, Huo X, Zhu F, Yang C, Tang H, Goldstein AC, Banwell BL, Hakonarson H, Xu H, Mingueneau M, Sun B, Li H, Bar-Or A (2024) Oxidative phosphorylation regulates B cell effector cytokines and promotes inflammation in multiple sclerosis. Immunol, Sci. https:\/\/doi.org\/10.1126\/sciimmunol.adk0865"},{"key":"2350_CR105","doi-asserted-by":"publisher","unstructured":"Z. Li, M. Bin Munim, D.A. Sharygin, B.J. Bevis, M.G. Vander Heiden, Understanding the Warburg Effect in Cancer, Cold Spring Harb. Perspect. Med. 15 (2025) a041532. https:\/\/doi.org\/10.1101\/cshperspect.a041532.","DOI":"10.1101\/cshperspect.a041532"},{"key":"2350_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103198","volume":"145","author":"M Lin","year":"2024","unstructured":"Lin M, Huang L, Huang J, Yu J, Yang X, Yang J (2024) Modulation of PKM2 inhibits follicular helper T cell differentiation and ameliorates inflammation in lupus-prone mice. J Autoimmun 145:103198. https:\/\/doi.org\/10.1016\/j.jaut.2024.103198","journal-title":"J Autoimmun"},{"key":"2350_CR107","doi-asserted-by":"publisher","DOI":"10.1080\/13510002.2025.2491845","author":"H-Y Lin","year":"2025","unstructured":"Lin H-Y, Ramos RB, Crawford DR (2025) Oxidation of human mitochondrial RNA strongly potentiates immunostimulation in an interferon-associated manner. Redox Rep. https:\/\/doi.org\/10.1080\/13510002.2025.2491845","journal-title":"Redox Rep"},{"key":"2350_CR108","doi-asserted-by":"publisher","unstructured":"T. Liu, S. Ren, C. Sun, P. Zhao, H. Wang, Glutaminolysis and peripheral CD4+ T cell differentiation: from mechanism to intervention strategy, Front. Immunol. 14 (2023). https:\/\/doi.org\/10.3389\/fimmu.2023.1221530.","DOI":"10.3389\/fimmu.2023.1221530"},{"key":"2350_CR109","doi-asserted-by":"publisher","unstructured":"C. Lopez, Role of Oxidative Phosphorylation and Glycolysis in Monocyte Immune Response, Bioenergetics 12 (2024) 1\u20132. https:\/\/doi.org\/10.35248\/2167-7662.24.12.265.","DOI":"10.35248\/2167-7662.24.12.265"},{"key":"2350_CR110","doi-asserted-by":"publisher","unstructured":"Y. Lu, Y. Wang, T. Ruan, Y. Wang, L. Ju, M. Zhou, L. Liu, D. Yao, M. Yao, Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases, Front. Immunol. 16 (2025). https:\/\/doi.org\/10.3389\/fimmu.2025.1536020.","DOI":"10.3389\/fimmu.2025.1536020"},{"key":"2350_CR111","doi-asserted-by":"publisher","unstructured":"Y. Ma, R. Song, C. Duan, Mitochondrial quality control and transfer communication in neurological disorders and neuroinflammation, Front. Immunol. 16 (2025). https:\/\/doi.org\/10.3389\/fimmu.2025.1542369.","DOI":"10.3389\/fimmu.2025.1542369"},{"key":"2350_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101924","volume":"11","author":"F Manai","year":"2022","unstructured":"Manai F, Amadio M (2022) Dimethyl fumarate triggers the antioxidant defense system in human retinal endothelial cells through Nrf2 activation. Antioxidants (Basel) 11:1924. https:\/\/doi.org\/10.3390\/antiox11101924","journal-title":"Antioxidants (Basel)"},{"key":"2350_CR113","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1172\/JCI10852","volume":"107","author":"G Martin","year":"2001","unstructured":"Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart J-C, Najib-Fruchart J, Glineur C, Staels B (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPAR\u03b1 and induces HDL apoA-I. J Clin Invest 107:1423\u20131432. https:\/\/doi.org\/10.1172\/JCI10852","journal-title":"J Clin Invest"},{"key":"2350_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606456","author":"C Mazewski","year":"2020","unstructured":"Mazewski C, Perez RE, Fish EN, Platanias LC (2020) Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.606456","journal-title":"Front Immunol"},{"key":"2350_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.114385","volume":"29","author":"HT Meitei","year":"2026","unstructured":"Meitei HT, Kulkarni N, Shirolkar A, Rapole S, Sharma PK, Mujeeb VR, Srivastava S, Lal G (2026) CCL20-CCR6 signaling alters the metabolic reprogramming to promote the pathogenic Th17 cell differentiation. iScience 29:114385. https:\/\/doi.org\/10.1016\/j.isci.2025.114385","journal-title":"iScience"},{"key":"2350_CR116","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.celrep.2018.01.040","volume":"22","author":"AV Menk","year":"2018","unstructured":"Menk AV, Scharping NE, Moreci RS, Zeng X, Guy C, Salvatore S, Bae H, Xie J, Young HA, Wendell SG, Delgoffe GM (2018) Early TCR signaling induces rapid aerobic glycolysis enabling distinct acute T cell effector functions. Cell Rep 22:1509\u20131521. https:\/\/doi.org\/10.1016\/j.celrep.2018.01.040","journal-title":"Cell Rep"},{"key":"2350_CR117","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","volume":"186","author":"RD Michalek","year":"2011","unstructured":"Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC (2011) Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 186:3299\u20133303. https:\/\/doi.org\/10.4049\/jimmunol.1003613","journal-title":"J Immunol"},{"key":"2350_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110132","volume":"27","author":"T Mirzapoiazova","year":"2024","unstructured":"Mirzapoiazova T, Tseng L, Mambetsariev B, Li H, Lou C-H, Pozhitkov A, Ramisetty SK, Nam S, Mambetsariev I, Armstrong B, Malhotra J, Arvanitis L, Nasser MW, Batra SK, Rosen ST, Wheeler DL, Singhal SS, Kulkarni P, Salgia R (2024) Teriflunomide\/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC. iScience 27:110132. https:\/\/doi.org\/10.1016\/j.isci.2024.110132","journal-title":"iScience"},{"key":"2350_CR119","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/13524585241234783","volume":"30","author":"X Montalban","year":"2024","unstructured":"Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS (2024) Efficacy and safety results after >3.5 years of treatment with the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: long-term follow-up of a phase II randomised clinical trial with a cerebrospinal fluid sub-study. Mult Scler J 30:558\u2013570. https:\/\/doi.org\/10.1177\/13524585241234783","journal-title":"Mult Scler J"},{"key":"2350_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240517","volume":"15","author":"T Moore","year":"2020","unstructured":"Moore T, Yanes RE, Calton MA, Vollrath D, Enns GM, Cowan TM (2020) AMP-independent activator of AMPK for treatment of mitochondrial disorders. PLoS ONE 15:e0240517. https:\/\/doi.org\/10.1371\/journal.pone.0240517","journal-title":"PLoS ONE"},{"key":"2350_CR121","doi-asserted-by":"publisher","unstructured":"S.A. Mosure, L.A. Solt. (2021) Uncovering New Challenges in Targeting Glycolysis to Treat Th17 Cell-Mediated Autoimmunity, Immunometabolism. https:\/\/doi.org\/10.20900\/immunometab20210006.","DOI":"10.20900\/immunometab20210006"},{"key":"2350_CR122","doi-asserted-by":"publisher","unstructured":"R.N. Muhammad, N.M. Aborehab, S.H. Aly, N.N. Nasr, M.O. Hindam, A.M. Mustafa, S.A. Faheem, M.H. Fawzy, M.E. Abo-El Fetoh, A.M. El-Dessouki, M.A. Rabie, R.A. El-Shiekh, M.E. Youssef, Natural products as HMG-CoA reductase inhibitors (statins) for the management of non-communicable diseases, Inflammopharmacology 34 (2026) 883\u2013918. https:\/\/doi.org\/10.1007\/s10787-025-02069-2.","DOI":"10.1007\/s10787-025-02069-2"},{"key":"2350_CR123","doi-asserted-by":"publisher","unstructured":"N.J. Mullen, S.K. Shukla, R. Thakur, S.S. Kollala, D. Wang, N. Chaika, J.F. Santana, W.R. Miklavcic, D.A. LaBreck, J.R. Mallareddy, D.H. Price, A. Natarajan, K. Mehla, D.B. Sykes, M.A. Hollingsworth, P.K. Singh, DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation, Elife 12 (2024). https:\/\/doi.org\/10.7554\/eLife.87292.","DOI":"10.7554\/eLife.87292"},{"key":"2350_CR124","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk4898","author":"B M\u00fcller-Durovic","year":"2024","unstructured":"M\u00fcller-Durovic B, J\u00e4ger J, Engelmann C, Schuhmachers P, Altermatt S, Schlup Y, Duthaler U, Makowiec C, Unterstab G, Roffeis S, Xhafa E, Assmann N, Trulsson F, Steiner R, Edwards-Hicks J, West J, Turner L, Develioglu L, Ivanek R, Azzi T, Dehio P, Berger C, Kuzmin D, Saboz S, Mautner J, L\u00f6liger J, Geigges M, Palianina D, Khanna N, Dirnhofer S, M\u00fcnz C, Bantug GR, Hess C, Berger C, Hess C, Koller M, Rossi S, Stampf S, M\u00fcller NJ (2024) A metabolic dependency of EBV can be targeted to hinder B cell transformation. Sci. https:\/\/doi.org\/10.1126\/science.adk4898","journal-title":"Sci"},{"key":"2350_CR125","doi-asserted-by":"publisher","unstructured":"R. Nafe, E. Hattingen, Pathogenesis of Multiple Sclerosis with Special Consideration of Iron Metabolism, Ferroptosis and Other Forms of Programmed Cell Death, Frontiers in Bioscience-Landmark 31 (2026). https:\/\/doi.org\/10.31083\/FBL45799.","DOI":"10.31083\/FBL45799"},{"key":"2350_CR126","doi-asserted-by":"publisher","unstructured":"M. Narine, H. Colognato, Current Insights Into Oligodendrocyte Metabolism and Its Power to Sculpt the Myelin Landscape, Front. Cell. Neurosci. 16 (2022). https:\/\/doi.org\/10.3389\/fncel.2022.892968.","DOI":"10.3389\/fncel.2022.892968"},{"key":"2350_CR127","doi-asserted-by":"publisher","unstructured":"M. Narine, M.A. Azmi, M. Umali, A. Volz, H. Colognato, The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation, Front. Cell. Neurosci. 17 (2023). https:\/\/doi.org\/10.3389\/fncel.2023.1254303.","DOI":"10.3389\/fncel.2023.1254303"},{"key":"2350_CR128","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.stem.2019.08.015","volume":"25","author":"B Neumann","year":"2019","unstructured":"Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, Foerster S, McClain CR, Chalut K, vanWijngaarden P, Franklin RJM (2019) Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell 25:473-485.e8. https:\/\/doi.org\/10.1016\/j.stem.2019.08.015","journal-title":"Cell Stem Cell"},{"key":"2350_CR129","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-immunol-081022-113627","volume":"41","author":"LG Ng","year":"2023","unstructured":"Ng LG, Liu Z, Kwok I, Ginhoux F (2023) Origin and heterogeneity of tissue myeloid cells: a focus on GMP-derived monocytes and neutrophils. Annu Rev Immunol 41:375\u2013404. https:\/\/doi.org\/10.1146\/annurev-immunol-081022-113627","journal-title":"Annu Rev Immunol"},{"key":"2350_CR130","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200166","volume-title":"Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin \u03b27+ Compartment","author":"M Nguyen Ky","year":"2023","unstructured":"Nguyen Ky M, Duran A, Hasantari I, Bru A, Deloire M, Brochet B, Ruet A, Schmitt N (2023) Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin \u03b27+ Compartment. Neuroimmunol. Neuroinflamm, Neurol. https:\/\/doi.org\/10.1212\/NXI.0000000000200166"},{"key":"2350_CR131","doi-asserted-by":"publisher","first-page":"25690","DOI":"10.1073\/pnas.2012249117","volume":"117","author":"N Nissimov","year":"2020","unstructured":"Nissimov N, Hajiyeva Z, Torke S, Grondey K, Br\u00fcck W, H\u00e4usser-Kinzel S, Weber MS (2020) B cells reappear less mature and more activated after their anti-CD20\u2013mediated depletion in multiple sclerosis. Proc Natl Acad Sci U S A 117:25690\u201325699. https:\/\/doi.org\/10.1073\/pnas.2012249117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2350_CR132","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/13524585251325468","volume":"31","author":"R Noroozi","year":"2025","unstructured":"Noroozi R, Tsai H-H, Yu K, Bronson P, Samuel K, Trinh K, Wei R, Tsai E, Briggs FB, Bhargava P, Fitzgerald KC (2025) Metabolic and lipid alterations in multiple sclerosis linked to disease severity. Mult Scler J 31:433\u2013443. https:\/\/doi.org\/10.1177\/13524585251325468","journal-title":"Mult Scler J"},{"key":"2350_CR133","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK (2017) Pleiotropic effects of statins on the cardiovascular system. Circ Res 120:229\u2013243. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308537","journal-title":"Circ Res"},{"key":"2350_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109225","volume":"27","author":"AE Oppong","year":"2024","unstructured":"Oppong AE, Coelewij L, Robertson G, Martin-Gutierrez L, Waddington KE, D\u00f6nnes P, Nytrova P, Farrell R, Pineda-Torra I, Jury EC (2024) Blood metabolomic and transcriptomic signatures stratify patient subgroups in multiple sclerosis according to disease severity. iScience 27:109225. https:\/\/doi.org\/10.1016\/j.isci.2024.109225","journal-title":"iScience"},{"key":"2350_CR135","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s12276-025-01535-9","volume":"57","author":"E Park","year":"2025","unstructured":"Park E, Ciofani M (2025) Th17 cell pathogenicity in autoimmune disease. Exp Mol Med 57:1913\u20131927. https:\/\/doi.org\/10.1038\/s12276-025-01535-9","journal-title":"Exp Mol Med"},{"key":"2350_CR136","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.21037\/jtd-23-778","volume":"15","author":"S Park","year":"2023","unstructured":"Park S, Lee EJ (2023) Lymphangioleiomyomatosis and mTOR inhibitors in real world\u2014a narrative review. J Thorac Dis 15:6333\u20136344. https:\/\/doi.org\/10.21037\/jtd-23-778","journal-title":"J Thorac Dis"},{"key":"2350_CR137","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/13524585261435409","volume":"32","author":"X Peng","year":"2026","unstructured":"Peng X, Bjornevik K, Clish CB, Edan G, Freedman MS, Hartung H-P, Montalb\u00e1n X, Sandbrink R, Kuhle J, Barkhof F, Wicklein E-M, Kappos L, Ascherio A, Cortese M (2026) Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years. Mult Scler J 32:696\u2013710. https:\/\/doi.org\/10.1177\/13524585261435409","journal-title":"Mult Scler J"},{"key":"2350_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00657","author":"NB Pikor","year":"2016","unstructured":"Pikor NB, Prat A, Bar-Or A, Gommerman JL (2016) Meningeal tertiary lymphoid tissues and multiple sclerosis: a gathering place for diverse types of immune cells during CNS autoimmunity. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00657","journal-title":"Front Immunol"},{"key":"2350_CR139","doi-asserted-by":"publisher","first-page":"11415","DOI":"10.1021\/acs.jmedchem.2c00573","volume":"65","author":"K Piorecka","year":"2022","unstructured":"Piorecka K, Kurjata J, Stanczyk WA (2022) Acriflavine, an acridine derivative for biomedical application: current state of the art. J Med Chem 65:11415\u201311432. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00573","journal-title":"J Med Chem"},{"key":"2350_CR140","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41389-025-00585-y","volume":"14","author":"JA Powell","year":"2025","unstructured":"Powell JA, Pitson SM (2025) Sphingosine 1-phosphate signalling in cancer stem cells. Oncogenesis 14:42. https:\/\/doi.org\/10.1038\/s41389-025-00585-y","journal-title":"Oncogenesis"},{"key":"2350_CR141","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40120-026-00931-1","volume":"15","author":"P Preziosa","year":"2026","unstructured":"Preziosa P, Guido G, Filippi M, Rocca MA (2026) Treatment effects on chronic active lesions in multiple sclerosis: current evidence and future perspectives. Neurol Ther 15:925\u2013949. https:\/\/doi.org\/10.1007\/s40120-026-00931-1","journal-title":"Neurol Ther"},{"key":"2350_CR142","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0275","author":"GSD Purvis","year":"2024","unstructured":"Purvis GSD, Collino M, van Dam AD, Einaudi G, Ng Y, Shanmuganathan M, Patel SY, Thiemermann C, Channon KM, Greaves DR (2024) OxPhos in adipose tissue macrophages regulated by BTK enhances their M2-like phenotype and confers a systemic immunometabolic benefit in obesity. Diabetes. https:\/\/doi.org\/10.2337\/db22-0275","journal-title":"Diabetes"},{"key":"2350_CR143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3003284","volume":"23","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, Xu Y, Ding X, Zhao C, Cheng H, Li G (2025) Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response. PLoS Biol 23:e3003284. https:\/\/doi.org\/10.1371\/journal.pbio.3003284","journal-title":"PLoS Biol"},{"key":"2350_CR144","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, Haboubi M, Halper J, Hosey JP, Jones DE, Lisak R, Pelletier D, Potrebic S, Sitcov C, Sommers R, Stachowiak J, Getchius TSD, Merillat SA, Pringsheim T (2018) Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis. Neurology 90:789\u2013800. https:\/\/doi.org\/10.1212\/WNL.0000000000005345","journal-title":"Neurology"},{"key":"2350_CR145","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1042\/BCJ20220325","volume":"481","author":"A Ragupathi","year":"2024","unstructured":"Ragupathi A, Kim C, Jacinto E (2024) The mTORC2 signaling network: targets and cross-talks. Biochem J 481:45\u201391. https:\/\/doi.org\/10.1042\/BCJ20220325","journal-title":"Biochem J"},{"key":"2350_CR146","doi-asserted-by":"publisher","unstructured":"D.S. Reich, D.L. Arnold, P. Vermersch, A. Bar-Or, R.J. Fox, A. Matta, T. Turner, E. Wallstr\u00f6m, X. Zhang, M. Mare\u0161, F.A. Khabirov, A. Traboulsee, F. Grand\u2019Maison, F. Jacques, A. Traboulsee, M. Tyblova, E. Meluzinova, R. Ampapa, M. Valis, P. Hradilke, M. Mare\u0161, P. Stourac, K. Gross-Paju, D. Laplaud, G. Mathey, B. Uitdehaag, E. Evdoshenkoo, E. Popova, M. Zakharova, N. Totolyan, I. Litvinenko, F. Khabirov, S. Sivertseva, V. Hancinova, E. Kantorova, M.L.M. Gines, X. Montalban, S.E. Maduano, J. Meca-Lallana, L. Rami\u00f3-Torrent\u00e0, T. Nehrych, V. Pashkovskyy, S. Moskovko, O. Kalbus, M. Khavunka, V. Pryshchepa, A. Goloborodko, D. Wynn, W. Honeycutt, S. Wray, B. Steingo, C. LaGanke, D. Huang, J.M. Hemphill, L. Goldstick, D. Robertson, Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial, Lancet Neurol. 20 (2021) 729\u2013738. https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4.","DOI":"10.1016\/S1474-4422(21)00237-4"},{"key":"2350_CR147","doi-asserted-by":"publisher","unstructured":"B. Ridley, S.M. Minozzi, M. Gonzalez-Lorenzo, C. Del Giovane, T. Piggott, G. Filippini, G. Peryer, M. Foschi, I. Tramacere, E. Baldin, F. Nonino, Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis, Cochrane Database of Systematic Reviews 2025 (2024). https:\/\/doi.org\/10.1002\/14651858.CD015443.pub2.","DOI":"10.1002\/14651858.CD015443.pub2"},{"key":"2350_CR148","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/icb.2016.55","volume":"94","author":"F Rizzo","year":"2016","unstructured":"Rizzo F, Giacomini E, Mechelli R, Buscarinu MC, Salvetti M, Severa M, Coccia EM (2016) Interferon-\u03b2 therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol Cell Biol 94:886\u2013894. https:\/\/doi.org\/10.1038\/icb.2016.55","journal-title":"Immunol Cell Biol"},{"key":"2350_CR149","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2217\/imt-2018-0153","volume":"11","author":"RR Robinson","year":"2019","unstructured":"Robinson RR, Dietz AK, Maroof AM, Asmis R, Forsthuber TG (2019) The role of glial\u2013neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain. Immunotherapy 11:129\u2013147. https:\/\/doi.org\/10.2217\/imt-2018-0153","journal-title":"Immunotherapy"},{"key":"2350_CR150","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61798","author":"SC Rosenkranz","year":"2021","unstructured":"Rosenkranz SC, Shaposhnykov AA, Tr\u00e4ger S, Engler JB, Witte ME, Roth V, Vieira V, Paauw N, Bauer S, Schwencke-Westphal C, Schubert C, Bal LC, Schattling B, Pless O, van Horssen J, Freichel M, Friese MA (2021) Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis. Elife. https:\/\/doi.org\/10.7554\/eLife.61798","journal-title":"Elife"},{"key":"2350_CR151","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1016\/j.immuni.2024.09.007","volume":"57","author":"JL Ross","year":"2024","unstructured":"Ross JL, Puigdelloses-Vallcorba M, Pi\u00f1ero G, Soni N, Thomason W, DeSisto J, Angione A, Tsankova NM, Castro MG, Schniederjan M, Wadhwani NR, Raju GP, Morgenstern P, Becher OJ, Green AL, Tsankov AM, Hambardzumyan D (2024) Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations. Immunity 57:2669-2687.e6. https:\/\/doi.org\/10.1016\/j.immuni.2024.09.007","journal-title":"Immunity"},{"key":"2350_CR152","doi-asserted-by":"publisher","unstructured":"S. Rumpf, N. Sanal, M. Marzano, Energy metabolic pathways in neuronal development and function, Oxford Open Neuroscience 2 (2023). https:\/\/doi.org\/10.1093\/oons\/kvad004.","DOI":"10.1093\/oons\/kvad004"},{"key":"2350_CR153","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a032037","volume":"9","author":"JJ Sabatino","year":"2019","unstructured":"Sabatino JJ, Zamvil SS, Hauser SL (2019) B-cell therapies in multiple sclerosis. Cold Spring Harb Perspect Med 9:a032037. https:\/\/doi.org\/10.1101\/cshperspect.a032037","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2350_CR154","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ana.27270","volume":"98","author":"JJ Sabatino","year":"2025","unstructured":"Sabatino JJ, Cree BAC, Hauser SL (2025) New horizons for multiple sclerosis therapy: 2025 and beyond. Ann Neurol 98:317\u2013328. https:\/\/doi.org\/10.1002\/ana.27270","journal-title":"Ann Neurol"},{"key":"2350_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03296-0","volume":"21","author":"M Sadeghdoust","year":"2024","unstructured":"Sadeghdoust M, Das A, Kaushik DK (2024) Fueling neurodegeneration: metabolic insights into microglia functions. J Neuroinflammation 21:300. https:\/\/doi.org\/10.1186\/s12974-024-03296-0","journal-title":"J Neuroinflammation"},{"key":"2350_CR156","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.autrev.2007.02.003","volume":"6","author":"W Schrempf","year":"2007","unstructured":"Schrempf W, Ziemssen T (2007) Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6:469\u2013475. https:\/\/doi.org\/10.1016\/j.autrev.2007.02.003","journal-title":"Autoimmun Rev"},{"key":"2350_CR157","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WCO.0000000000000938","volume":"34","author":"F Sellebjerg","year":"2021","unstructured":"Sellebjerg F, Weber MS (2021) Targeting B cells in multiple sclerosis. Curr Opin Neurol 34:295\u2013302. https:\/\/doi.org\/10.1097\/WCO.0000000000000938","journal-title":"Curr Opin Neurol"},{"key":"2350_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0411-4","volume":"15","author":"VK Senanayake","year":"2015","unstructured":"Senanayake VK, Jin W, Mochizuki A, Chitou B, Goodenowe DB (2015) Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study. BMC Neurol 15:154. https:\/\/doi.org\/10.1186\/s12883-015-0411-4","journal-title":"BMC Neurol"},{"key":"2350_CR159","doi-asserted-by":"publisher","DOI":"10.1007\/S12035-025-05348-9","author":"VK Sharma","year":"2025","unstructured":"Sharma VK (2025) Microbiota-derived SCFAs in multiple sclerosis: from immune priming to neurodegeneration. Mol Neurobiol. https:\/\/doi.org\/10.1007\/S12035-025-05348-9","journal-title":"Mol Neurobiol"},{"key":"2350_CR160","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s12192-013-0480-5","volume":"19","author":"Z Shen","year":"2014","unstructured":"Shen Z, Liu C, Liu P, Zhao J, Xu W (2014) Sphingosine 1-phosphate (S1P) promotes mitochondrial biogenesis in Hep G2 cells by activating peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1 (PGC-1\u03b1). Cell Stress Chaperones 19:541\u2013548. https:\/\/doi.org\/10.1007\/s12192-013-0480-5","journal-title":"Cell Stress Chaperones"},{"key":"2350_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1670379","author":"Z Sheng","year":"2026","unstructured":"Sheng Z, Luo Q, Liu X, Yang X (2026) Bioactives and exercise synergize to modulate AMPK and inflammation. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1670379","journal-title":"Front Immunol"},{"key":"2350_CR162","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1084\/jem.20110278","volume":"208","author":"LZ Shi","year":"2011","unstructured":"Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H (2011) HIF1\u03b1\u2013dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 208:1367\u20131376. https:\/\/doi.org\/10.1084\/jem.20110278","journal-title":"J Exp Med"},{"key":"2350_CR163","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02403-1","volume":"11","author":"Y Shi","year":"2025","unstructured":"Shi Y, Zhang H, Miao C (2025) Metabolic reprogram and T cell differentiation in inflammation: current evidence and future perspectives. Cell Death Discov 11:123. https:\/\/doi.org\/10.1038\/s41420-025-02403-1","journal-title":"Cell Death Discov"},{"key":"2350_CR164","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1007\/s10787-025-01955-z","volume":"33","author":"MM Shokr","year":"2025","unstructured":"Shokr MM (2025) Beyond the blood\u2013brain barrier: unraveling T cell subsets in CNS immunity and disease. Inflammopharmacology 33:5799\u20135818. https:\/\/doi.org\/10.1007\/s10787-025-01955-z","journal-title":"Inflammopharmacology"},{"key":"2350_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26189207","volume":"26","author":"J Smusz","year":"2025","unstructured":"Smusz J, Mojsak P, Matys P, Miro\u0144czuk A, Tarasiuk J, Grubczak K, Starosz A, Kochanowicz J, Ku\u0142akowska A, Ruszczy\u0144ska K, Kapica-Topczewska K (2025) Metabolomics in multiple sclerosis: advances, challenges, and clinical perspectives\u2014a systematic review. Int J Mol Sci 26:9207. https:\/\/doi.org\/10.3390\/ijms26189207","journal-title":"Int J Mol Sci"},{"key":"2350_CR166","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/glia.24648","volume":"73","author":"AL Soung","year":"2025","unstructured":"Soung AL, Kyauk RV, Pandey S, Shen YA, Reichelt M, Lin H, Jiang Z, Kirshnamoorthy P, Foreman O, Lauffer BE, Yuen TJ (2025) Modulation of OPC mitochondrial function by inhibiting USP30 promotes their differentiation. Glia 73:773\u2013787. https:\/\/doi.org\/10.1002\/glia.24648","journal-title":"Glia"},{"key":"2350_CR167","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.clim.2017.06.006","volume":"181","author":"M Spadaro","year":"2017","unstructured":"Spadaro M, Montarolo F, Perga S, Martire S, Brescia F, Malucchi S, Bertolotto A (2017) Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10 years in responder multiple sclerosis patients. Clin Immunol 181:83\u201388. https:\/\/doi.org\/10.1016\/j.clim.2017.06.006","journal-title":"Clin Immunol"},{"key":"2350_CR168","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4049\/jimmunol.1701477","volume":"201","author":"I-H Sun","year":"2018","unstructured":"Sun I-H, Oh M-H, Zhao L, Patel CH, Arwood ML, Xu W, Tam AJ, Blosser RL, Wen J, Powell JD (2018) MTOR complex 1 signaling regulates the generation and function of central and effector Foxp3+ regulatory T cells. J Immunol 201:481\u2013492. https:\/\/doi.org\/10.4049\/jimmunol.1701477","journal-title":"J Immunol"},{"key":"2350_CR169","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/s42255-025-01386-8","volume":"7","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhang W-W, Men L, Wu J, Yao L, Huang X, Wu Y, Zhang C, Chen Y, Carling D, Zhang C-S, Lin S-C (2025b) Oligodendrocyte precursor cell-specific blocking of low-glucose-induced activation of AMPK ensures myelination and remyelination. Nat Metab 7:2324\u20132345. https:\/\/doi.org\/10.1038\/s42255-025-01386-8","journal-title":"Nat Metab"},{"key":"2350_CR170","doi-asserted-by":"publisher","unstructured":"X.-G. Sun, X.-H. Chu, I.S. Godje Godje, S.-Y. Liu, H.-Y. Hu, Y.-B. Zhang, L.-J. Zhu, H. Wang, C. Sui, J. Huang, Y.-J. Shen, Aerobic Glycolysis Induced by mTOR\/HIF-1\u03b1 Promotes Early Brain Injury After Subarachnoid Hemorrhage via Activating M1 Microglia, Transl. Stroke Res. 15 (2024) 1\u201315. https:\/\/doi.org\/10.1007\/s12975-022-01105-5.","DOI":"10.1007\/s12975-022-01105-5"},{"key":"2350_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604987","author":"X Sun","year":"2025","unstructured":"Sun X, Zhang F, Wang L, Lee G, Yang S, Zhou D, Chang B, Hu B, Zho Y (2025a) Immunological microenvironment and targeted therapeutics in multiple sclerosis: new insights in crosstalk between immune niches and CNS. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1604987","journal-title":"Front Immunol"},{"key":"2350_CR172","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/nm.4181","volume":"22","author":"RU Svensson","year":"2016","unstructured":"Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A, Vera L, Gerken L, Greenwood J, Bhat S, Harriman G, Westlin WF, Harwood HJ, Saghatelian A, Kapeller R, Metallo CM, Shaw RJ (2016) Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med 22:1108\u20131119. https:\/\/doi.org\/10.1038\/nm.4181","journal-title":"Nat Med"},{"key":"2350_CR173","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s42255-023-00838-3","volume":"5","author":"Y-H Tai","year":"2023","unstructured":"Tai Y-H, Engels D, Locatelli G, Emmanouilidis I, Fecher C, Theodorou D, M\u00fcller SA, Licht-Mayer S, Kreutzfeldt M, Wagner I, de Mello NP, Gkotzamani S-N, Trov\u00f2 L, Kendirli A, Aljovi\u0107 A, Breckwoldt MO, Naumann R, Bareyre FM, Perocchi F, Mahad D, Merkler D, Lichtenthaler SF, Kerschensteiner M, Misgeld T (2023) Targeting the TCA cycle can ameliorate widespread axonal energy deficiency in neuroinflammatory lesions. Nat Metab 5:1364\u20131381. https:\/\/doi.org\/10.1038\/s42255-023-00838-3","journal-title":"Nat Metab"},{"key":"2350_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105099","volume":"103","author":"H Tang","year":"2024","unstructured":"Tang H, Dilimulati D, Yang Z, Zhou K, Chen X, Sun R, Wang N, Liang Z, Bian S, Zhao J, Song P, Zheng S, Wang H, Xie H (2024) Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy. EBioMedicine 103:105099. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105099","journal-title":"EBioMedicine"},{"key":"2350_CR175","doi-asserted-by":"publisher","unstructured":"G. Tilly, M. Cadoux, A. Garcia, J. Morille, S. Wiertlewski, C. Pecqueur, S. Brouard, D. Laplaud, N. Degauque, Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells, Front. Immunol. 12 (2021). https:\/\/doi.org\/10.3389\/fimmu.2021.730342.","DOI":"10.3389\/fimmu.2021.730342"},{"key":"2350_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417223","volume":"24","author":"D Tonev","year":"2023","unstructured":"Tonev D, Momchilova A (2023) Oxidative stress and the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in multiple sclerosis: focus on certain exogenous and endogenous Nrf2 activators and therapeutic plasma exchange modulation. Int J Mol Sci 24:17223. https:\/\/doi.org\/10.3390\/ijms242417223","journal-title":"Int J Mol Sci"},{"key":"2350_CR177","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179572","author":"MA Torres Acosta","year":"2025","unstructured":"Torres Acosta MA, Gurkan JK, Liu Q, Mambetsariev N, Reyes Flores C, Helmin KA, Joudi AM, Morales-Nebreda L, Cheng K, Abdala-Valencia H, Weinberg SE, Singer BD (2025) AMPK is necessary for Treg functional adaptation to microenvironmental stress during malignancy and viral pneumonia. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI179572","journal-title":"J Clin Invest"},{"key":"2350_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101359","volume":"54","author":"M Trojano","year":"2025","unstructured":"Trojano M, Paolicelli D (2025) Targeting smouldering neuroinflammation in multiple sclerosis: insights from tolebrutinib clinical trials. Lancet Reg Health Eur 54:101359. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101359","journal-title":"Lancet Reg Health Eur"},{"key":"2350_CR179","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","volume":"24","author":"TJ Turner","year":"2024","unstructured":"Turner TJ, Brun P, Gruber RC, Ofengeim D (2024) Comparative CNS pharmacology of the Bruton\u2019s tyrosine kinase (BTK) inhibitor tolebrutinib versus other BTK inhibitor candidates for treating multiple sclerosis. Drugs R D 24:263\u2013274. https:\/\/doi.org\/10.1007\/s40268-024-00468-4","journal-title":"Drugs R D"},{"key":"2350_CR180","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/imcb.70027","volume":"103","author":"N Valentini","year":"2025","unstructured":"Valentini N, Requejo Cier CJ, Lamarche C (2025) Highlights of 2024: Tregs immunometabolism and how to counter inflammatory niches. Immunol Cell Biol 103:504\u2013508. https:\/\/doi.org\/10.1111\/imcb.70027","journal-title":"Immunol Cell Biol"},{"key":"2350_CR181","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41590-025-02407-0","volume":"27","author":"FJ van Haften","year":"2026","unstructured":"van Haften FJ, van der Sluis TC, Hepp HS, M\u00fclling N, Nadafi R, Sampadi B, van Duikeren S, Mostert JS, van der Sterre R, van Veelen PA, Heieis GA, Veerkamp DMB, Wesselink TH, Vleeshouwers W, Beijnes M, Pardieck IN, van Horssen ELF, de Groot AF, van der Ploeg M, Kroep JR, de Miranda NFCC, van der Zanden SY, Neefjes J, Mei H, Vertegaal ACO, Everts B, van der Burg SH, Arens R (2026) Cell cycle arrest enhances CD8+ T cell effector function by potentiating glucose metabolism and IL-2 signaling. Nat Immunol 27:463\u2013475. https:\/\/doi.org\/10.1038\/s41590-025-02407-0","journal-title":"Nat Immunol"},{"key":"2350_CR182","doi-asserted-by":"publisher","unstructured":"J.F. Varghese, B.J. Kaskow, F. von Glehn, J. Case, Z. Li, A.M. Jul\u00e9, E. Berdan, S.J. Ho Sui, Y. Hu, R. Krishnan, T. Chitnis, V.K. Kuchroo, H.L. Weiner, C.M. Baecher-Allan, Human regulatory memory B cells defined by expression of TIM-1 and TIGIT are dysfunctional in multiple sclerosis, Front. Immunol. 15 (2024). https:\/\/doi.org\/10.3389\/fimmu.2024.1360219.","DOI":"10.3389\/fimmu.2024.1360219"},{"key":"2350_CR183","doi-asserted-by":"publisher","unstructured":"\u00c1.A. Vergara Nieto, A.H. Diaz, M. Hern\u00e1ndez, D. Sagredo, A Narrative Review about Metabolic Pathways, Molecular Mechanisms and Clinical Implications of Intermittent Fasting as Autophagy Promotor, Curr. Nutr. Rep. 14 (2025) 78. https:\/\/doi.org\/10.1007\/s13668-025-00666-9.","DOI":"10.1007\/s13668-025-00666-9"},{"key":"2350_CR184","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051095","volume":"10","author":"D Vi\u0161nji\u0107","year":"2021","unstructured":"Vi\u0161nji\u0107 D, Lali\u0107 H, Dembitz V, Tomi\u0107 B, Smoljo T (2021) AICAr, a widely used AMPK activator with important AMPK-independent effects: a systematic review. Cells 10:1095. https:\/\/doi.org\/10.3390\/cells10051095","journal-title":"Cells"},{"key":"2350_CR185","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.2147\/OTT.S159095","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J, Li J, Cao N, Li Z, Han J, Li L (2018) Resveratrol, an activator of SIRT1, induces protective autophagy in non-small-cell lung cancer via inhibiting Akt\/mTOR and activating p38-MAPK. Onco Targets Ther 11:7777\u20137786. https:\/\/doi.org\/10.2147\/OTT.S159095","journal-title":"Onco Targets Ther"},{"key":"2350_CR186","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12974-024-03016-8","volume":"21","author":"P-F Wang","year":"2024","unstructured":"Wang P-F, Jiang F, Zeng Q-M, Yin W-F, Hu Y-Z, Li Q, Hu Z-L (2024) Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis. J Neuroinflammation 21:28. https:\/\/doi.org\/10.1186\/s12974-024-03016-8","journal-title":"J Neuroinflammation"},{"key":"2350_CR187","doi-asserted-by":"publisher","first-page":"5924","DOI":"10.1038\/s44318-025-00569-z","volume":"44","author":"Y-H Wang","year":"2025","unstructured":"Wang Y-H, Wang L, Ho P-C (2025a) Decoding immunometabolism with next-generation tools: lessons from dendritic cells and T cells. EMBO J 44:5924\u20135939. https:\/\/doi.org\/10.1038\/s44318-025-00569-z","journal-title":"EMBO J"},{"key":"2350_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115799","volume":"44","author":"C Wang","year":"2025","unstructured":"Wang C, Wagner A, Fessler J, DeTomaso D, Zaghouani S, Zhou Y, Pierce K, Sobel RA, Clish C, Yosef N, Kuchroo VK (2025b) The glycolytic reaction PGAM restrains Th17 pathogenicity and Th17-dependent autoimmunity. Cell Rep 44:115799. https:\/\/doi.org\/10.1016\/j.celrep.2025.115799","journal-title":"Cell Rep"},{"key":"2350_CR189","doi-asserted-by":"publisher","unstructured":"Z. Wang, D. Guan, S. Wang, L.Y.A. Chai, S. Xu, K.-P. Lam, Glycolysis and Oxidative Phosphorylation Play Critical Roles in Natural Killer Cell Receptor-Mediated Natural Killer Cell Functions, Front. Immunol. 11 (2020). https:\/\/doi.org\/10.3389\/fimmu.2020.00202.","DOI":"10.3389\/fimmu.2020.00202"},{"key":"2350_CR190","doi-asserted-by":"publisher","unstructured":"J. Wei, J. Moon, Y. Yasumizu, L. Zhang, K. Radassi, N. Buitrago-Pocasangre, M.E. Deerhake, N. Strauli, C.-W. Chen, A. Herman, R. Pedotti, C. Raposo, I. Yim, J. Pappalardo, E.E. Longbrake, T.S. Sumida, P.-P. Axisa, D.A. Hafler, Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell changes in multiple sclerosis, Journal of Clinical Investigation 135 (2025). https:\/\/doi.org\/10.1172\/JCI182790.","DOI":"10.1172\/JCI182790"},{"key":"2350_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/cells14070552","volume":"14","author":"AG Willison","year":"2025","unstructured":"Willison AG, Hagler R, Weise M, Elben S, Huntemann N, Masanneck L, Pfeuffer S, Lichtenberg S, Golombeck KS, Preuth L-M, Rolfes L, \u00d6zt\u00fcrk M, Ruck T, Melzer N, Korsen M, Hauser SL, Hartung H-P, Lang PA, Pawlitzki M, R\u00e4uber S, Meuth SG (2025) Effects of anti-CD20 antibody therapy on immune cell dynamics in relapsing-remitting multiple sclerosis. Cells 14:552. https:\/\/doi.org\/10.3390\/cells14070552","journal-title":"Cells"},{"key":"2350_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104719","volume":"75","author":"Q Wu","year":"2023","unstructured":"Wu Q, Wang Q, Yang J, Mills EA, Chilukuri P, Saad A, Dowling CA, Fisher C, Kirch B, Mao-Draayer Y (2023) Teriflunomide modulates both innate and adaptive immune capacities in multiple sclerosis. Mult Scler Relat Disord 75:104719. https:\/\/doi.org\/10.1016\/j.msard.2023.104719","journal-title":"Mult Scler Relat Disord"},{"key":"2350_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2025.107179","volume":"217","author":"H Wu","year":"2025","unstructured":"Wu H, Mi Y, Zheng C, Zhang Y, Xu S, Zhu J, Jin T (2025a) Metabolic reprogramming of glial cells: fatty acid pathways as regulators of remyelination in multiple sclerosis. Neurobiol Dis 217:107179. https:\/\/doi.org\/10.1016\/j.nbd.2025.107179","journal-title":"Neurobiol Dis"},{"key":"2350_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103633","volume":"89","author":"C-Y Wu","year":"2025","unstructured":"Wu C-Y, Reynolds WC, Abril I, McManus AJ, Brenner C, Gonz\u00e1lez-Irizarry G, Guti\u00e9rrez-Mart\u00ednez L, Sun O, Rosand J, Tanzi RE, Arnold SE, Guzm\u00e1n-V\u00e9lez E (2025b) Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine 89:103633. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103633","journal-title":"EClinicalMedicine"},{"key":"2350_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114148","volume":"149","author":"X Xia","year":"2025","unstructured":"Xia X, Chen W, Zhou T, Zhou F, Lu C, Yan Z, Zhao Q, Su Q (2025) TEPP-46 inhibits glycolysis to promote M2 polarization of microglia after ischemic stroke. Int Immunopharmacol 149:114148. https:\/\/doi.org\/10.1016\/j.intimp.2025.114148","journal-title":"Int Immunopharmacol"},{"key":"2350_CR196","doi-asserted-by":"publisher","unstructured":"C. Xinyan, W. Yajie, H. Shangfan, Y. Yuefei, L. Junwei, Z. Jiaqiao, J. Huiming, mTOR-autophagy axis regulation by intermittent fasting promotes skeletal muscle growth and differentiation, Nutr. Metab. (Lond). 22 (2025) 109. https:\/\/doi.org\/10.1186\/s12986-025-01001-3.","DOI":"10.1186\/s12986-025-01001-3"},{"key":"2350_CR197","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26083585","volume":"26","author":"R Yamasaki","year":"2025","unstructured":"Yamasaki R (2025) Microglia\/macrophages in autoimmune demyelinating encephalomyelitis (multiple sclerosis\/neuromyelitis optica). Int J Mol Sci 26:3585. https:\/\/doi.org\/10.3390\/ijms26083585","journal-title":"Int J Mol Sci"},{"key":"2350_CR198","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1007\/s00277-024-05998-0","volume":"103","author":"L Yang","year":"2024","unstructured":"Yang L, Ma D, Liu S, Zou L (2024) The DHODH inhibitor teriflunomide impedes cell proliferation and enhances chemosensitivity to daunorubicin (DNR) in T-cell acute lymphoblastic leukemia. Ann Hematol 103:5449\u20135460. https:\/\/doi.org\/10.1007\/s00277-024-05998-0","journal-title":"Ann Hematol"},{"key":"2350_CR199","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583587","author":"Y Ye","year":"2025","unstructured":"Ye Y, Wang Y, Xu Q, Liu J, Yang Z, Wuren T, Ge R-L (2025) In vitro study: HIF-1\u03b1-dependent glycolysis enhances NETosis in hypoxic conditions. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1583587","journal-title":"Front Immunol"},{"key":"2350_CR200","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.2147\/IJN.S254574","volume":"15","author":"M-S Yoon","year":"2020","unstructured":"Yoon M-S (2020) Nanotechnology-Based Targeting of mTOR Signaling in Cancer. Int J Nanomedicine 15:5767\u20135781. https:\/\/doi.org\/10.2147\/IJN.S254574","journal-title":"Int J Nanomedicine"},{"key":"2350_CR201","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"Y-H Youm","year":"2015","unstructured":"Youm Y-H, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D\u2019Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD (2015) The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome\u2013mediated inflammatory disease. Nat Med 21:263\u2013269. https:\/\/doi.org\/10.1038\/nm.3804","journal-title":"Nat Med"},{"key":"2350_CR202","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1189\/jlb.3AB0417-159RR","volume":"102","author":"KE Young","year":"2017","unstructured":"Young KE, Flaherty S, Woodman KM, Sharma-Walia N, Reynolds JM (2017) Fatty acid synthase regulates the pathogenicity of Th17 cells. J Leukoc Biol 102:1229\u20131235. https:\/\/doi.org\/10.1189\/jlb.3AB0417-159RR","journal-title":"J Leukoc Biol"},{"key":"2350_CR203","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21608\/odr.2025.347446.1046","volume":"6","author":"AA Zarief","year":"2025","unstructured":"Zarief AA (2025) Pleiotropic effect of statins: beyond cholesterol reduction. Octahedron Drug Research 6:40\u201349. https:\/\/doi.org\/10.21608\/odr.2025.347446.1046","journal-title":"Octahedron Drug Research"},{"key":"2350_CR204","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb6296","volume-title":"B cells polarize pathogenic inflammatory T helper subsets through ICOSL-dependent glycolysis","author":"Q-H Zeng","year":"2020","unstructured":"Zeng Q-H, Wei Y, Lao X-M, Chen D-P, Huang C-X, Lin Q-Y, He M, Liao Y, Zheng L, Li B, Zhang G-B, Chen Y, Kuang D-M (2020) B cells polarize pathogenic inflammatory T helper subsets through ICOSL-dependent glycolysis. Adv, Sci. https:\/\/doi.org\/10.1126\/sciadv.abb6296"},{"key":"2350_CR205","doi-asserted-by":"publisher","first-page":"19579","DOI":"10.1073\/pnas.0809763105","volume":"105","author":"H Zhang","year":"2008","unstructured":"Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL (2008) Digoxin and other cardiac glycosides inhibit HIF-1\u03b1 synthesis and block tumor growth. Proc Natl Acad Sci U S A 105:19579\u201319586. https:\/\/doi.org\/10.1073\/pnas.0809763105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2350_CR206","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01807-9","volume":"10","author":"S Zhang","year":"2024","unstructured":"Zhang S, Lv K, Liu Z, Zhao R, Li F (2024) Fatty acid metabolism of immune cells: a new target of tumour immunotherapy. Cell Death Discov 10:39. https:\/\/doi.org\/10.1038\/s41420-024-01807-9","journal-title":"Cell Death Discov"},{"key":"2350_CR207","doi-asserted-by":"publisher","unstructured":"Y. Zhang, Z. Pei, Z. Wen, Y. Chen, H. Wang, W. Tan, X. Chen, J. Liu, Q. Ni, Nuclear receptor-driven immunometabolic crosstalk: immune-centric pharmacology targeting the inflamed nexus, Front. Cell Dev. Biol. 13 (2026). https:\/\/doi.org\/10.3389\/fcell.2025.1706384.","DOI":"10.3389\/fcell.2025.1706384"},{"key":"2350_CR208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1680688","author":"T Zhong","year":"2025","unstructured":"Zhong T, Cao Q, Ma Z, Jiang C (2025) Metabolic regulation of interferon-mediated innate antiviral immunity. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1680688","journal-title":"Front Immunol"},{"key":"2350_CR209","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12967-024-06061-2","volume":"23","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Xue F (2025) Unlocking new potential: the evolving landscape of metformin repurposing trials. J Transl Med 23:24. https:\/\/doi.org\/10.1186\/s12967-024-06061-2","journal-title":"J Transl Med"},{"key":"2350_CR210","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/imm.13554","volume":"167","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Zhang X, Xie S, Bao W, Chen J, Wu Q, Lai X, Liu L, Xiong S, Peng Y (2022) Oxidative phosphorylation regulates interleukin\u201010 production in regulatory B cells via the extracellular signal\u2010related kinase pathway. Immunology 167:576\u2013589. https:\/\/doi.org\/10.1111\/imm.13554","journal-title":"Immunology"},{"key":"2350_CR211","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040273","volume":"103","author":"B Zhu","year":"2024","unstructured":"Zhu B, Cheng L, Huang B, Liu R, Ren B (2024) Central role of hypoxia-inducible factor-1\u03b1 in metabolic reprogramming of cancer cells: a review. Medicine (Baltimore) 103:e40273. https:\/\/doi.org\/10.1097\/MD.0000000000040273","journal-title":"Medicine (Baltimore)"},{"key":"2350_CR212","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12974-025-03474-8","volume":"22","author":"W Zhu","year":"2025","unstructured":"Zhu W, Revu S, Chen C, Dahl M, Ramkumar A, Kelly C, McGeachy MJ, Xia Z (2025) Aging-dependent change in Th17 and cytokine response in multiple sclerosis. J Neuroinflammation 22:150. https:\/\/doi.org\/10.1186\/s12974-025-03474-8","journal-title":"J Neuroinflammation"},{"key":"2350_CR213","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11033-026-11478-7","volume":"53","author":"E Zingkou","year":"2026","unstructured":"Zingkou E, Medoro A, Davinelli S, Saso L, Sotiropoulou G, Pampalakis G (2026) Dimethyl fumarate as a versatile therapeutic agent: molecular mechanisms and potential clinical applications. Mol Biol Rep 53:344. https:\/\/doi.org\/10.1007\/s11033-026-11478-7","journal-title":"Mol Biol Rep"},{"key":"2350_CR214","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13024-024-00742-8","volume":"19","author":"O Zveik","year":"2024","unstructured":"Zveik O, Rechtman A, Ganz T, Vaknin-Dembinsky A (2024) The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells. Mol Neurodegener 19:53. https:\/\/doi.org\/10.1186\/s13024-024-00742-8","journal-title":"Mol Neurodegener"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02350-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02350-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02350-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:13:16Z","timestamp":1788963196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02350-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":214,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2350"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02350-y","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}